Such genomic alterations in RET have been identified in a variety of tumor types, including RET mutations in medullary thyroid cancer (nearly all for hereditary and 25–50% for sporadic) and RET fusions in non-small cell lung cancer (1–2%) and papillary thyroid cancer (10%), and less frequently in other types of tumors [2,6,7,8,9,10,11]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.